Paul J Healy1, Philip S Helliwell. 1. Wellington Regional Rheumatology Unit, Hutt Valley District Health Board, Lower Hutt, New Zealand. paul.healy@huttvalleydhb.org.nz
Abstract
OBJECTIVE: To assess responsiveness of the Psoriatic Arthritis Quality of Life tool (PsAQoL) and add further data regarding the construct validity of PsAQoL. METHODS: Twenty-eight patients with PsA underwent clinical assessment over a period of 6 months after change of disease modifying therapy, usually to methotrexate. Measures of outcome included PsAQoL, Health Assessment Questionnaire (HAQ), and assessment of disease activity. RESULTS: PsAQoL revealed significant change at 3 and 6 months. Standardized response mean was large at 3 months and small at 6 months. There was strong correlation with other patient-derived measures such as the HAQ and Patient Global at all timepoints. Disease Activity Score-28 and Physician Global showed a relationship with PsAQoL at 3 and 6 months, while a tender joint count relationship was seen only at 6 months. CONCLUSION: The PsAQoL now has responsiveness data and a measure of construct validity to sit alongside previously demonstrated reliability data. Our study has compared the change characteristcs within a group of patients. The next step in the development will require a placebo controlled trial to test discrimination between patients undergoing active treatment or takingplacebo.
RCT Entities:
OBJECTIVE: To assess responsiveness of the Psoriatic Arthritis Quality of Life tool (PsAQoL) and add further data regarding the construct validity of PsAQoL. METHODS: Twenty-eight patients with PsA underwent clinical assessment over a period of 6 months after change of disease modifying therapy, usually to methotrexate. Measures of outcome included PsAQoL, Health Assessment Questionnaire (HAQ), and assessment of disease activity. RESULTS:PsAQoL revealed significant change at 3 and 6 months. Standardized response mean was large at 3 months and small at 6 months. There was strong correlation with other patient-derived measures such as the HAQ and Patient Global at all timepoints. Disease Activity Score-28 and Physician Global showed a relationship with PsAQoL at 3 and 6 months, while a tender joint count relationship was seen only at 6 months. CONCLUSION: The PsAQoL now has responsiveness data and a measure of construct validity to sit alongside previously demonstrated reliability data. Our study has compared the change characteristcs within a group of patients. The next step in the development will require a placebo controlled trial to test discrimination between patients undergoing active treatment or taking placebo.
Authors: Freke Wink; Suzanne Arends; Stephen P McKenna; Pieternella M Houtman; Elisabeth Brouwer; Anneke Spoorenberg Journal: PLoS One Date: 2013-02-13 Impact factor: 3.240
Authors: William Tillett; Ade Adebajo; Mel Brooke; Willemina Campbell; Laura C Coates; Oliver FitzGerald; Laure Gossec; Philip Helliwell; Sarah Hewlett; Jana James; Patricia Minnock; Aisling Reast; Dennis O'Sullivan; Maarten de Wit; Neil McHugh Journal: Curr Rheumatol Rep Date: 2014-05 Impact factor: 4.592
Authors: Gary J Macfarlane; Rosemary J Hollick; LaKrista Morton; Maureen Heddle; Eva-Maria Bachmair; R Stuart Anderson; Daniel Whibley; Karen Forrest Keenan; Peter Murchie; Kevin Stelfox; Marcus J Beasley; Gareth T Jones Journal: Rheumatology (Oxford) Date: 2021-10-09 Impact factor: 7.580
Authors: U Kiltz; I Andreica; M Igelmann; L Kalthoff; D Krause; E Schmitz; S P McKenna; J Braun Journal: Z Rheumatol Date: 2021-03 Impact factor: 1.372